neotanshinlactone

06/11/2009 - "In a continuing study, we explored how the individual rings in neo-tanshinlactone (1) influence its potent and selective in vitro antibreast cancer activity. "
01/01/2011 - "Compound 15 was the most potent analog compared with structurally related neo-tanshinlactone (e.g., 1) and 4-amino-2H-benzo[h]chromen-2-one (ABO, e.g., 4) analogs, and thus merits further exploration as an anti-cancer drug candidate."
01/01/2007 - "Recently, in the author's laboratory, a new compound, neo-tanshinlactone, was discovered to have potent selective antibreast cancer activity. "
11/04/2004 - "Neo-tanshinlactone (1) was isolated and synthesized for the first time and evaluated in vitro against several human cancer cell lines. "
01/01/2011 - "In our ongoing modification study of neo-tanshinlactone (1), we discovered 2-(furan-2-yl)naphthalen-1-ol (FNO) derivatives 3 and 4 as a new class of anti-tumor agents. "

09/07/2006 - "In our previous study, neo-tanshinlactone (1) showed potent and selective anti-breast cancer activity. "
01/01/2017 - "Neo-tanshinlactone (NTL) a natural product is known for its specificity and selectivity towards the breast cancer cells. "
01/01/2017 - "Neo-tanshinlactone D-ring modified novel analogues induce apoptosis in human breast cancer cell via DNA damage."
01/01/2016 - "Our results suggest that neo-tanshinlactone is a promising regimen for ER+ breast tumors."
01/01/2016 - "The selective anti-proliferative effect of neo-tanshinlactone was associated with the induction of apoptosis in ER+ breast cancer cells. "

01/01/2022 - "Four series of molecular hybrids (37 final products) of neo-tanshinlactone, a natural product extracted from Salvia miltiorrhiza Bunge, and known PD-1/PD-L1 interaction inhibitors were prepared as possible chemotherapeutic agents against triple negative breast cancer. "

07/23/2012 - "DYZ-2-90, a novel neo-tanshinlactone ring-opened compound, induces ERK-mediated mitotic arrest and subsequent apoptosis by activating JNK in human colorectal cancer cells."